amphetamine has been researched along with Parkinson Disease in 139 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This has not been assessed in a Parkinson's disease population." | 3.11 | Amphetamine-induced dopamine release and impulsivity in Parkinson's disease. ( Aumann, M; Claassen, DO; Donahue, MJ; Hay, KR; Kang, H; Song, AK; Stark, AJ; Trujillo, P; Yan, Y; Zald, DH, 2022) |
| "Cabergoline plasma levels were measured on day 30, and then after administration of cabergoline (1 mg/day) alone for further 22 days." | 2.68 | Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline. ( Bosc, M; Deffond, D; Dordain, G; Dostert, P; Fiorentini, F; La Croix, R; Persiani, S; Strolin Benedetti, M; Vernay, D, 1995) |
| " Dextroamphetamine in lower dosage also reduced disability by some 17 percent." | 2.64 | Amphetamines in the treatment of Parkinson's disease. ( Asselman, P; Bovill, KT; Marsden, CD; Parkes, JD; Phipps, JA; Rose, P; Tarsy, D, 1975) |
| "With the exception of Parkinson's disease, there is little evidence that treatments which decrease DA function are potent inducers of depression, but it is argued that such a relationship might not necessarily be expected." | 2.36 | Dopamine and depression: a review of recent evidence. I. Empirical studies. ( Willner, P, 1983) |
| " The water solubility and improved bioavailability may help reduce medication frequency associated with l-DOPA treatment of PD." | 1.43 | DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. ( Atlas, D, 2016) |
| " A new formulation, an orally disintegrating tablet (ODT), has recently been introduced to overcome these pharmacokinetic problems by avoiding its presystemic metabolism." | 1.39 | The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease. ( Magyar, K; Szökő, E; Tábi, T; Vécsei, L, 2013) |
| "Parkinson's disease is characterized by progressive degeneration of dopaminergic neurons." | 1.39 | The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson's disease. ( Agari, T; Date, I; Kadota, T; Kameda, M; Kikuchi, Y; Liang, H; Shinko, A; Thomas Tayra, J; Vcelar, B; Wakamori, T; Wang, F; Weik, R; Yasuhara, T, 2013) |
| "Graft-induced dyskinesias (GIDs), side-effects found in clinical grafting trials for Parkinson's disease (PD), may be associated with the withdrawal of immunosuppression." | 1.35 | The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors. ( Collier, TJ; Freeman, TB; McGuire, SO; Meredith, G; Soderstrom, KE; Sortwell, CE; Steece-Collier, K; Wu, Q, 2008) |
| "Animal models of Parkinson's disease have been widely used for investigating the mechanisms of neurodegenerative process and for discovering alternative strategies for treating the disease." | 1.35 | Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. ( Kurz, MJ; Lau, YS; Pothakos, K, 2009) |
| " We now show that they are associated with the chronic administration of L-DOPA prior to the transplantation surgery." | 1.35 | Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. ( Brundin, P; Cenci, MA; Lane, EL; Vercammen, L, 2009) |
| "In the unilateral rat model of Parkinson's disease (PD), amphetamine induced rotation is widely used as an index of both lesion deficits and of graft-derived recovery." | 1.34 | Amphetamine induced rotation in the assessment of lesions and grafts in the unilateral rat model of Parkinson's disease. ( Dunnett, SB; Torres, EM, 2007) |
| "In a rat model of Parkinson's disease, animals with unilateral 6-hydroxydopamine lesions of the median forebrain bundle received dopamine-rich ventral mesencephalic grafts derived from embryos of crown to rump length 4, 6, 9, or 10." | 1.34 | Improved survival of young donor age dopamine grafts in a rat model of Parkinson's disease. ( Bagga, V; Dunnett, SB; Gates, MA; Monville, C; Torres, EM, 2007) |
| " Dose-response analysis for total AIM scores yielded a levodopa ED50 value of 3." | 1.34 | Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. ( Belknap, JK; Johnson, SW; Kozell, LB; Munhall, AC; Putterman, DB, 2007) |
| " In a primary culture of E14 murine ventral mesencephalic neurons, earlier treatment with the higher dosage of GDNF suppressed 6-OHDA-induced loss of dopaminergic neurons better than later treatment." | 1.33 | Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. ( Date, I; Kameda, M; Kobayashi, K; Matsui, T; Miyoshi, Y; Muraoka, K; Shingo, T; Takeuchi, A; Wenji, Y; Yano, A; Yasuhara, T, 2005) |
| "The poor survival of dopamine grafts in Parkinson's disease is one of the main obstacles to the widespread application of this therapy." | 1.33 | Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor age. ( Castro, MG; Dunnett, SB; Lowenstein, PR; Monville, C; Torres, EM, 2005) |
| ""Amphetamine exposure" was defined as a prior use of amphetamine, methamphetamine or dextroamphetamine." | 1.33 | Amphetamine exposure is elevated in Parkinson's disease. ( Bekele, W; Christine, CW; Garwood, ER; McCulloch, CE, 2006) |
| "In rodent models of Parkinson's disease (PD) blockade of these receptors increases locomotion and enhances the actions of dopamine (DA) replacement therapy." | 1.33 | Effect of ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in Parkinsonian rats. In vivo microdialysis study. ( Biedka, I; Brus, R; Drosik, M; Kostrzewa, RM; Nowak, P; Szczerbak, G, 2006) |
| "Dopaminergic lesion produced catalepsy and hypoactivity." | 1.32 | Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. ( Schmidt, WJ; Srinivasan, J, 2004) |
| "We have used a rat model of Parkinson's disease (PD) to address issues of importance for a future clinical application of dopamine (DA) neuron grafting in patients with PD." | 1.27 | Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release. ( Astedt, B; Björklund, A; Brundin, P; Clarke, DJ; Lindvall, O; Nilsson, OG; Strecker, RE; Widner, H, 1988) |
| " Terguride has both agonist and antagonist actions at striatal dopamine receptors, but chronic administration did not produce behavioral supersensitivity." | 1.27 | Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease. ( Herbster, G; Koller, WC, 1987) |
| " Although directly related to daily dosage of levodopa, the myoclonus was specifically blocked by the serotonin antagonist, methysergide." | 1.25 | Levodopa-induced myoclonus. ( Bergen, D; Goetz, C; Klawans, HL, 1975) |
| " Prolonged pretreatment with suprathreshold doses of amphetamine decreased the threshold dosage of both amphetamine and apomorphine necessary to elicit stereotyped behavior." | 1.25 | Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias. ( Crossett, P; Dana, N; Klawans, HL, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 41 (29.50) | 18.7374 |
| 1990's | 16 (11.51) | 18.2507 |
| 2000's | 44 (31.65) | 29.6817 |
| 2010's | 33 (23.74) | 24.3611 |
| 2020's | 5 (3.60) | 2.80 |
| Authors | Studies |
|---|---|
| Song, AK | 1 |
| Hay, KR | 1 |
| Trujillo, P | 1 |
| Aumann, M | 1 |
| Stark, AJ | 1 |
| Yan, Y | 1 |
| Kang, H | 1 |
| Donahue, MJ | 1 |
| Zald, DH | 1 |
| Claassen, DO | 1 |
| Rees, D | 1 |
| Beynon, AL | 1 |
| Lelos, MJ | 1 |
| Smith, GA | 2 |
| Roberts, LD | 1 |
| Phelps, L | 1 |
| Dunnett, SB | 9 |
| Morgan, AH | 1 |
| Brown, RM | 1 |
| Wells, T | 1 |
| Davies, JS | 1 |
| Warnecke, AMP | 1 |
| Kang, MS | 1 |
| Jakowec, MW | 1 |
| Davies, DL | 1 |
| Masato, A | 1 |
| Bubacco, L | 2 |
| Greggio, E | 1 |
| Antipova, V | 1 |
| Holzmann, C | 1 |
| Hawlitschka, A | 1 |
| Witt, M | 1 |
| Wree, A | 1 |
| Frankl, JA | 1 |
| Bose, S | 1 |
| Kuo, PH | 1 |
| Faustini, G | 1 |
| Longhena, F | 1 |
| Varanita, T | 1 |
| Pizzi, M | 1 |
| Missale, C | 1 |
| Benfenati, F | 1 |
| Björklund, A | 11 |
| Spano, P | 1 |
| Bellucci, A | 1 |
| Hernando, S | 1 |
| Requejo, C | 1 |
| Herran, E | 1 |
| Ruiz-Ortega, JA | 1 |
| Morera-Herreras, T | 1 |
| Lafuente, JV | 1 |
| Ugedo, L | 1 |
| Gainza, E | 1 |
| Pedraz, JL | 1 |
| Igartua, M | 1 |
| Hernandez, RM | 1 |
| McKinley, JW | 1 |
| Shi, Z | 1 |
| Kawikova, I | 1 |
| Hur, M | 1 |
| Bamford, IJ | 1 |
| Sudarsana Devi, SP | 1 |
| Vahedipour, A | 1 |
| Darvas, M | 1 |
| Bamford, NS | 1 |
| Tábi, T | 1 |
| Szökő, E | 1 |
| Vécsei, L | 1 |
| Magyar, K | 1 |
| Casas, S | 1 |
| Giuliani, F | 1 |
| Cremaschi, F | 1 |
| Yunes, R | 1 |
| Cabrera, R | 1 |
| Petri, D | 1 |
| Pum, M | 1 |
| Vesper, J | 1 |
| Huston, JP | 1 |
| Schnitzler, A | 1 |
| Perfeito, R | 1 |
| Cunha-Oliveira, T | 1 |
| Rego, AC | 1 |
| Heuer, A | 1 |
| Klein, A | 1 |
| Vinh, NN | 1 |
| Lane, EL | 4 |
| Summerson, SR | 1 |
| Kemere, CT | 1 |
| Aazhang, B | 1 |
| Shin, E | 2 |
| Rogers, JT | 1 |
| Devoto, P | 1 |
| Carta, M | 3 |
| Collier, TJ | 3 |
| O'Malley, J | 1 |
| Rademacher, DJ | 1 |
| Stancati, JA | 1 |
| Sisson, KA | 1 |
| Sortwell, CE | 3 |
| Paumier, KL | 1 |
| Gebremedhin, KG | 1 |
| Steece-Collier, K | 2 |
| Keber, U | 1 |
| Klietz, M | 1 |
| Carlsson, T | 2 |
| Oertel, WH | 2 |
| Weihe, E | 1 |
| Schäfer, MK | 1 |
| Höglinger, GU | 1 |
| Depboylu, C | 1 |
| Schwerk, A | 1 |
| Altschüler, J | 1 |
| Roch, M | 1 |
| Gossen, M | 1 |
| Winter, C | 2 |
| Berg, J | 1 |
| Kurtz, A | 1 |
| Akyüz, L | 1 |
| Steiner, B | 2 |
| Atlas, D | 1 |
| Runeberg-Roos, P | 1 |
| Piccinini, E | 1 |
| Penttinen, AM | 1 |
| Mätlik, K | 1 |
| Heikkinen, H | 1 |
| Kuure, S | 1 |
| Bespalov, MM | 1 |
| Peränen, J | 1 |
| Garea-Rodríguez, E | 1 |
| Fuchs, E | 1 |
| Airavaara, M | 1 |
| Kalkkinen, N | 1 |
| Penn, R | 1 |
| Saarma, M | 1 |
| Ztaou, S | 1 |
| Maurice, N | 1 |
| Camon, J | 1 |
| Guiraudie-Capraz, G | 1 |
| Kerkerian-Le Goff, L | 1 |
| Beurrier, C | 1 |
| Liberge, M | 1 |
| Amalric, M | 1 |
| Jensen, P | 1 |
| Pedersen, EG | 1 |
| Zimmer, J | 1 |
| Widmer, HR | 2 |
| Meyer, M | 2 |
| McCoy, MK | 1 |
| Ruhn, KA | 1 |
| Martinez, TN | 1 |
| McAlpine, FE | 1 |
| Blesch, A | 1 |
| Tansey, MG | 1 |
| Soderstrom, KE | 1 |
| Meredith, G | 1 |
| Freeman, TB | 1 |
| McGuire, SO | 1 |
| Wu, Q | 1 |
| Soulet, D | 1 |
| Vercammen, L | 2 |
| Cenci, MA | 3 |
| Brundin, P | 6 |
| Fujita, Y | 1 |
| Takahashi, K | 1 |
| Takei, M | 1 |
| Niitsu, H | 1 |
| Aoki, Y | 1 |
| Onodera, M | 1 |
| Fujino, Y | 1 |
| Inoue, Y | 1 |
| Endo, S | 1 |
| Pothakos, K | 1 |
| Kurz, MJ | 1 |
| Lau, YS | 1 |
| Dusonchet, J | 1 |
| Bensadoun, JC | 1 |
| Schneider, BL | 2 |
| Aebischer, P | 2 |
| Andereggen, L | 1 |
| Guzman, R | 1 |
| Ducray, AD | 1 |
| Fasano, A | 1 |
| Petrovic, I | 1 |
| Grealish, S | 1 |
| Mattsson, B | 3 |
| Draxler, P | 1 |
| Belin, AC | 1 |
| Westerlund, M | 1 |
| Anvret, A | 1 |
| Lindqvist, E | 1 |
| Pernold, K | 1 |
| Ogren, SO | 1 |
| Duester, G | 1 |
| Galter, D | 1 |
| Laganiere, J | 1 |
| Kells, AP | 1 |
| Lai, JT | 1 |
| Guschin, D | 1 |
| Paschon, DE | 1 |
| Meng, X | 1 |
| Fong, LK | 1 |
| Yu, Q | 1 |
| Rebar, EJ | 1 |
| Gregory, PD | 1 |
| Bankiewicz, KS | 1 |
| Forsayeth, J | 1 |
| Zhang, HS | 1 |
| Falk, T | 1 |
| Yue, X | 1 |
| Zhang, S | 1 |
| McCourt, AD | 1 |
| Yee, BJ | 1 |
| Gonzalez, RT | 1 |
| Sherman, SJ | 1 |
| Decressac, M | 2 |
| Ulusoy, A | 1 |
| Georgievska, B | 3 |
| Romero-Ramos, M | 1 |
| Kirik, D | 3 |
| McFarland, K | 1 |
| Price, DL | 1 |
| Bonhaus, DW | 1 |
| Lundblad, M | 1 |
| Weikop, P | 1 |
| Garcia, J | 1 |
| Winkler, C | 3 |
| García-Montes, JR | 1 |
| Boronat-García, A | 1 |
| López-Colomé, AM | 1 |
| Bargas, J | 1 |
| Guerra-Crespo, M | 1 |
| Drucker-Colín, R | 1 |
| Müller, T | 1 |
| Hoffmann, JA | 1 |
| Dimpfel, W | 1 |
| Oehlwein, C | 1 |
| Wang, M | 1 |
| Lu, C | 1 |
| Roisen, F | 1 |
| Smith, ES | 1 |
| Geissler, SA | 1 |
| Schallert, T | 2 |
| Lee, HJ | 1 |
| Thomas Tayra, J | 1 |
| Kameda, M | 4 |
| Yasuhara, T | 5 |
| Agari, T | 2 |
| Kadota, T | 1 |
| Wang, F | 1 |
| Kikuchi, Y | 1 |
| Liang, H | 1 |
| Shinko, A | 1 |
| Wakamori, T | 1 |
| Vcelar, B | 1 |
| Weik, R | 1 |
| Date, I | 5 |
| Bezard, E | 1 |
| Tronci, E | 1 |
| Pioli, EY | 1 |
| Li, Q | 1 |
| Porras, G | 1 |
| Olds, ME | 2 |
| Jacques, DB | 2 |
| Kpoyov, O | 1 |
| Kronstrand, R | 1 |
| Ahlner, J | 1 |
| Dizdar, N | 1 |
| Larson, G | 1 |
| SCHWAB, RS | 1 |
| ENGLAND, AC | 1 |
| AUQUIER, L | 1 |
| BONIS, A | 1 |
| HAMBURGER, J | 1 |
| LHERMITTE, F | 1 |
| PEQUIGNOT, H | 1 |
| Forsback, S | 1 |
| Niemi, R | 1 |
| Marjamäki, P | 1 |
| Eskola, O | 1 |
| Bergman, J | 1 |
| Grönroos, T | 1 |
| Haaparanta, M | 1 |
| Haapalinna, A | 1 |
| Rinne, J | 1 |
| Solin, O | 1 |
| Sajadi, A | 1 |
| Shingo, T | 4 |
| Kobayashi, K | 2 |
| Takeuchi, A | 3 |
| Yano, A | 3 |
| Muraoka, K | 4 |
| Matsui, T | 3 |
| Miyoshi, Y | 3 |
| Hamada, H | 3 |
| Srinivasan, J | 1 |
| Schmidt, WJ | 1 |
| Kopyov, O | 1 |
| Lacar, B | 1 |
| Dong, Z | 1 |
| Wolfer, DP | 1 |
| Lipp, HP | 1 |
| Büeler, H | 1 |
| Wenji, Y | 1 |
| Ogura, T | 1 |
| Ogata, M | 1 |
| Akita, H | 1 |
| Jitsuki, S | 1 |
| Akiba, L | 1 |
| Noda, K | 1 |
| Hoka, S | 1 |
| Saji, M | 1 |
| wen Ji, Y | 2 |
| Nishio, S | 1 |
| Iancu, R | 1 |
| Mohapel, P | 1 |
| Paul, G | 1 |
| Hayase, H | 1 |
| Borlongan, CV | 1 |
| Meissner, KK | 1 |
| Kirkham, DL | 1 |
| Doering, LC | 1 |
| Johansson, S | 1 |
| Lee, IH | 1 |
| Olson, L | 1 |
| Spenger, C | 1 |
| Dowd, E | 1 |
| Monville, C | 3 |
| Torres, EM | 4 |
| Wong, LF | 1 |
| Azzouz, M | 1 |
| Mazarakis, ND | 1 |
| Lowenstein, PR | 1 |
| Castro, MG | 1 |
| Puschban, Z | 1 |
| Stefanova, N | 1 |
| Petersén, A | 1 |
| Poewe, W | 1 |
| Wenning, GK | 1 |
| Hosman, K | 1 |
| Siebert, E | 1 |
| Kempermann, G | 1 |
| Petrus, DS | 1 |
| Kupsch, A | 2 |
| Garwood, ER | 1 |
| Bekele, W | 1 |
| McCulloch, CE | 1 |
| Christine, CW | 1 |
| Nishida, K | 1 |
| Itoh, S | 1 |
| Inoue, N | 1 |
| Kudo, K | 1 |
| Ikeda, N | 1 |
| Fleming, SM | 1 |
| Salcedo, J | 1 |
| Hutson, CB | 1 |
| Rockenstein, E | 1 |
| Masliah, E | 1 |
| Levine, MS | 1 |
| Chesselet, MF | 1 |
| Chiang, YH | 1 |
| Lin, SZ | 1 |
| Zhou, FC | 1 |
| Nowak, P | 1 |
| Szczerbak, G | 1 |
| Biedka, I | 1 |
| Drosik, M | 1 |
| Kostrzewa, RM | 1 |
| Brus, R | 1 |
| Gates, MA | 1 |
| Bagga, V | 1 |
| Putterman, DB | 1 |
| Munhall, AC | 1 |
| Kozell, LB | 1 |
| Belknap, JK | 1 |
| Johnson, SW | 1 |
| Quinn, M | 1 |
| Mukhida, K | 2 |
| Sadi, D | 1 |
| Hong, M | 2 |
| Mendez, I | 2 |
| Kääriäinen, TM | 1 |
| Piltonen, M | 1 |
| Ossola, B | 1 |
| Kekki, H | 1 |
| Lehtonen, S | 1 |
| Nenonen, T | 1 |
| Lecklin, A | 1 |
| Raasmaja, A | 1 |
| Männistö, PT | 1 |
| Baghbaderani, BA | 1 |
| Lewington, M | 1 |
| Phillips, T | 1 |
| McLeod, M | 1 |
| Sen, A | 1 |
| Behie, LA | 1 |
| Wray, SR | 1 |
| Melville, GN | 1 |
| Grell, GA | 1 |
| Edge, PC | 1 |
| Willner, P | 1 |
| Sahgal, A | 1 |
| Andrews, JS | 1 |
| Biggins, JA | 1 |
| Candy, JM | 1 |
| Edwardson, JA | 1 |
| Keith, AB | 1 |
| Turner, JD | 1 |
| Wright, C | 1 |
| Stern, GM | 3 |
| Lees, AJ | 3 |
| Hardie, R | 1 |
| Sandler, M | 4 |
| Hardie, RJ | 1 |
| Elsworth, JD | 1 |
| Ward, C | 1 |
| Ossowska, K | 1 |
| Nikkhah, G | 1 |
| Bentlage, C | 1 |
| Cunningham, MG | 1 |
| Hudson, JL | 1 |
| van Horne, CG | 1 |
| Strömberg, I | 1 |
| Brock, S | 1 |
| Clayton, J | 1 |
| Masserano, J | 1 |
| Hoffer, BJ | 1 |
| Gerhardt, GA | 1 |
| Yurek, DM | 1 |
| Lu, W | 1 |
| Hipkens, S | 1 |
| Wiegand, SJ | 1 |
| Earl, CD | 1 |
| Reum, T | 1 |
| Xie, JX | 1 |
| Sautter, J | 1 |
| Morgenstern, R | 1 |
| Dostert, P | 1 |
| Strolin Benedetti, M | 1 |
| Persiani, S | 1 |
| La Croix, R | 1 |
| Bosc, M | 1 |
| Fiorentini, F | 1 |
| Deffond, D | 1 |
| Vernay, D | 1 |
| Dordain, G | 1 |
| Seeman, P | 1 |
| Madras, BK | 1 |
| Daley, BF | 1 |
| Barker, RA | 1 |
| Klein, RL | 1 |
| Lewis, MH | 1 |
| Muzyczka, N | 1 |
| Meyer, EM | 1 |
| Connor, B | 1 |
| Kozlowski, DA | 1 |
| Tillerson, JL | 1 |
| Davidson, BL | 1 |
| Bohn, MC | 1 |
| Rosenblad, C | 1 |
| Bjorklund, LM | 1 |
| Sánchez-Pernaute, R | 1 |
| Chung, S | 1 |
| Andersson, T | 1 |
| Chen, IY | 1 |
| McNaught, KS | 1 |
| Brownell, AL | 1 |
| Jenkins, BG | 1 |
| Wahlestedt, C | 1 |
| Kim, KS | 1 |
| Isacson, O | 1 |
| Richfield, EK | 1 |
| Thiruchelvam, MJ | 1 |
| Cory-Slechta, DA | 1 |
| Wuertzer, C | 1 |
| Gainetdinov, RR | 1 |
| Caron, MG | 1 |
| Di Monte, DA | 1 |
| Federoff, HJ | 1 |
| Reynolds, GP | 1 |
| Riederer, P | 1 |
| Barry, VC | 1 |
| Klawans, HL | 3 |
| Kakimoto, Y | 1 |
| Goetz, C | 1 |
| Bergen, D | 1 |
| Parkes, JD | 1 |
| Tarsy, D | 1 |
| Marsden, CD | 3 |
| Bovill, KT | 1 |
| Phipps, JA | 1 |
| Rose, P | 1 |
| Asselman, P | 1 |
| Crossett, P | 1 |
| Dana, N | 1 |
| Arushanian, EB | 2 |
| Carman, LS | 1 |
| Gage, FH | 1 |
| Shults, CW | 1 |
| Curran, EJ | 2 |
| Becker, JB | 2 |
| Blunt, SB | 1 |
| Jenner, P | 1 |
| Freed, WJ | 1 |
| Poltorak, M | 1 |
| Annett, LE | 1 |
| Martel, FL | 1 |
| Rogers, DC | 1 |
| Ridley, RM | 1 |
| Baker, HF | 1 |
| Strecker, RE | 1 |
| Widner, H | 1 |
| Clarke, DJ | 1 |
| Nilsson, OG | 1 |
| Astedt, B | 1 |
| Lindvall, O | 1 |
| Koller, WC | 1 |
| Herbster, G | 1 |
| Poirier, LJ | 1 |
| Langelier, P | 1 |
| Bédard, P | 1 |
| Boucher, R | 1 |
| Larochelle, L | 1 |
| Parent, A | 1 |
| Roberge, AG | 1 |
| Birkmayer, W | 1 |
| Nelson, SR | 2 |
| Walaszek, EJ | 2 |
| Snyder, SH | 1 |
| Hornykiewicz, O | 2 |
| Naylor, RJ | 2 |
| Costall, B | 2 |
| Wright, T | 1 |
| Pakkenberg, H | 1 |
| Bottcher, J | 1 |
| Miller, E | 1 |
| Nieburg, HA | 1 |
| Ungerstedt, U | 1 |
| Ljungberg, T | 1 |
| Steg, G | 1 |
| Yahr, MD | 1 |
| Duvoisin, RC | 1 |
| Tolosa, E | 1 |
| Wender, PH | 1 |
| Bianchine, JR | 1 |
| Sunyapridakul, L | 1 |
| Friedhoff, AJ | 1 |
| Alpert, M | 1 |
| Mumenthaler, M | 1 |
| North, RR | 1 |
| Beani, L | 1 |
| Bianchi, C | 1 |
| Gomirato, G | 1 |
| Perfetti, C | 1 |
| Cartei, M | 1 |
| Umbach, W | 2 |
| Stoliarov, GV | 1 |
| Tolpyshev, BA | 1 |
| Völler, GW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuroactive Steroids in Acute Ischemic Stroke: Association With Cognitive, Functional and Neurological Outcomes.[NCT02914106] | 60 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| Changes in Plasma Cortisol, Brain-derived Neurotrophic Factor, and Nitrites in Patients With Acute Ischemic Stroke[NCT03242304] | 40 participants (Actual) | Observational | 2016-04-01 | Completed | |||
| Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2021-05-31 | Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study) | ||
| Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study[NCT03843944] | Phase 4 | 20 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| Therapeutic Drug Monitoring of Corticosteroids/β2-agonists in Hair in Asthmatic Patients: an Open-label Feasibility Study[NCT03691961] | 24 participants (Actual) | Interventional | 2018-09-20 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for amphetamine and Parkinson Disease
| Article | Year |
|---|---|
The Amphetamine Induced Rotation Test: A Re-Assessment of Its Use as a Tool to Monitor Motor Impairment and Functional Recovery in Rodent Models of Parkinson's Disease.
Topics: Amphetamine; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Do | 2019 |
Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Topics: alpha-Synuclein; Amphetamine; Dopaminergic Neurons; Humans; Illicit Drugs; Mitochondria; Oxidative S | 2013 |
Insights into pathophysiology of punding reveal possible treatment strategies.
Topics: Amphetamine; Behavior, Addictive; Clinical Protocols; Cocaine; Corpus Striatum; Dopamine Agonists; H | 2010 |
Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder.
Topics: Amphetamine; Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Avoidance | 1981 |
Dopamine and depression: a review of recent evidence. I. Empirical studies.
Topics: Amphetamine; Antipsychotic Agents; Brain; Bromocriptine; Depressive Disorder; Dihydroxyphenylalanine | 1983 |
The role of excitatory amino acids in experimental models of Parkinson's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Catalepsy; Disease M | 1994 |
Anti-hyperactivity medication: methylphenidate and amphetamine.
Topics: Adult; Amino Acid Sequence; Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Cen | 1998 |
On the role of dopamine in the pathophysiology of anorexia nervosa.
Topics: 17-Ketosteroids; Amphetamine; Anorexia Nervosa; Apomorphine; Compulsive Personality Disorder; Dopami | 1976 |
Pharmacology of the central nervous system.
Topics: Abnormalities, Drug-Induced; Acetylcholine; Adrenocorticotropic Hormone; Amphetamine; Anger; Angiote | 1968 |
Putative neurotransmitters in the brain: selective neuronal uptake, subcellular localization, and interactions with centrally acting drugs.
Topics: Aminobutyrates; Amphetamine; Animals; Behavior; Brain; Brain Chemistry; Carbon Isotopes; Catecholami | 1970 |
Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).
Topics: Amphetamine; Animals; Basal Ganglia; Brain Chemistry; Butyrophenones; Corpus Striatum; Dihydroxyphen | 1973 |
Drug therapy of parkinsonism.
Topics: Amantadine; Amitriptyline; Amphetamine; Antiparkinson Agents; Dihydroxyphenylalanine; Drug Antagonis | 1972 |
Parkinson's disease; modern treatment.
Topics: Amantadine; Amphetamine; Antidepressive Agents; Antiparkinson Agents; Aromatic Amino Acid Decarboxyl | 1973 |
Some speculations concerning a possible biochemical basis of minimal brain dysfunction.
Topics: Acute Disease; Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior; Behavi | 1974 |
Individualization of levodopa therapy.
Topics: Amantadine; Amphetamine; Anesthetics; Animals; Antihypertensive Agents; Apomorphine; Arrhythmias, Ca | 1974 |
[Clinical aspects and drug therapy of Parkinson's syndrome].
Topics: Amphetamine; Diphenhydramine; Humans; Parasympatholytics; Parkinson Disease; Parkinson Disease, Post | 1966 |
Pharmacology of the central nervous system.
Topics: Acetylcholine; Amphetamine; Analgesics; Anesthetics; Animals; Anticonvulsants; Behavior; Brain; Cate | 1969 |
Pharmacology and pathophysiology of dopaminergic neurons.
Topics: Amphetamine; Animals; Basal Ganglia Diseases; Brain; Butyrophenones; Cats; Cattle; Dopamine; Ganglia | 1971 |
6 trials available for amphetamine and Parkinson Disease
| Article | Year |
|---|---|
Amphetamine-induced dopamine release and impulsivity in Parkinson's disease.
Topics: Aged; Amphetamine; Autoreceptors; Dextroamphetamine; Dopamine; Humans; Impulsive Behavior; Ligands; | 2022 |
Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication.
Topics: Aged; Aged, 80 and over; Amphetamine; Amphetamines; Antiparkinson Agents; Drug Administration Schedu | 2003 |
Clinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease.
Topics: Amphetamine; Clinical Trials as Topic; Double-Blind Method; Humans; Hydrogen-Ion Concentration; Park | 1983 |
Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline.
Topics: Aged; Amphetamine; Amphetamines; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Drug Interact | 1995 |
Amphetamines in the treatment of Parkinson's disease.
Topics: Aged; Amantadine; Amphetamine; Clinical Trials as Topic; Female; Humans; Isomerism; Levodopa; Male; | 1975 |
[10 years of L-DOPA therapy of Parkinson's syndrome].
Topics: Administration, Oral; Amphetamine; Animals; Brain Chemistry; Catecholamines; Clinical Trials as Topi | 1971 |
115 other studies available for amphetamine and Parkinson Disease
| Article | Year |
|---|---|
Acyl-Ghrelin Attenuates Neurochemical and Motor Deficits in the 6-OHDA Model of Parkinson's Disease.
Topics: Amphetamine; Animals; Dopamine; Dopaminergic Neurons; Mice; Oxidopamine; Parkinson Disease; Rats | 2023 |
The macrocyclic lactones ivermectin and moxidectin show differential effects on rotational behavior in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Disease Models, Animal; Female; Ivermectin; | 2020 |
Too much for your own good: Excessive dopamine damages neurons and contributes to Parkinson's disease: An Editorial Highlight for "Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metabolites,
Topics: Amphetamine; Animals; Catecholamines; Dopamine; Dopaminergic Neurons; Mice; Oxidative Stress; Parkin | 2021 |
Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Botulinum Toxins, Type A | 2021 |
False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine.
Topics: Amphetamine; Dextroamphetamine; Dopamine Plasma Membrane Transport Proteins; False Positive Reaction | 2018 |
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Topics: alpha-Synuclein; Amphetamine; Animals; Central Nervous System Stimulants; Dependovirus; Mice; Mice, | 2018 |
Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation.
Topics: Amphetamine; Animals; Antioxidants; Corpus Striatum; Dopamine; Dopamine Agents; Dopaminergic Neurons | 2019 |
Dopamine Deficiency Reduces Striatal Cholinergic Interneuron Function in Models of Parkinson's Disease.
Topics: Acetylcholine; Amphetamine; Animals; Cholinergic Neurons; Cyclic AMP-Dependent Protein Kinases; Dise | 2019 |
The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Topics: Administration, Oral; Amphetamine; Biological Availability; Drug Evaluation; Humans; Levodopa; Monoa | 2013 |
Neuromodulatory effect of progesterone on the dopaminergic, glutamatergic, and GABAergic activities in a male rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; G | 2013 |
Neuromodulatory effect of progesterone on the dopaminergic, glutamatergic, and GABAergic activities in a male rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; G | 2013 |
Neuromodulatory effect of progesterone on the dopaminergic, glutamatergic, and GABAergic activities in a male rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; G | 2013 |
Neuromodulatory effect of progesterone on the dopaminergic, glutamatergic, and GABAergic activities in a male rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; G | 2013 |
GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Animals; Disease Models, Animal; Diz | 2013 |
Amphetamine-induced dyskinesia in the transplanted hemi-Parkinsonian mouse.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Cell Transplantation; Corpus Striatum | 2012 |
Current amplitude-dependent modulation of rotational behavior with GPi stimulation in the rodent model of Parkinson's Disease.
Topics: Amphetamine; Animals; Basal Ganglia; Behavior, Animal; Deep Brain Stimulation; Disease Models, Anima | 2013 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benz | 2014 |
Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.
Topics: Aging; Amphetamine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Ph | 2015 |
Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Amphetamine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Dru | 2015 |
Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson's disease.
Topics: Adipose Tissue; Amphetamine; Animals; Anti-Inflammatory Agents; Cognition; Disease Models, Animal; D | 2015 |
DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Topics: Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase | 2016 |
Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease.
Topics: Amphetamine; Animals; CHO Cells; Cricetulus; Disease Models, Animal; Drug Design; Genetic Variation; | 2016 |
Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Choline O-Acetyltransferase; Choliner | 2016 |
Functional effect of FGF2- and FGF8-expanded ventral mesencephalic precursor cells in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Cells, Cultured; Central Nervous System S | 2008 |
Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats.
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Cell Nucleus; Cells, Cultured; Cytoplasm; Dependoviru | 2008 |
The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Ani | 2008 |
Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Antiparkins | 2008 |
Detection of levorotatory methamphetamine and levorotatory amphetamine in urine after ingestion of an overdose of selegiline.
Topics: Adult; Amphetamine; Biomarkers; Drug Overdose; Gas Chromatography-Mass Spectrometry; Humans; Male; M | 2008 |
Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Ataxia; Disease Models, Animal; | 2009 |
Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease.
Topics: Amphetamine; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Chromatography, High Pres | 2009 |
Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, An | 2009 |
Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Brain; Cell Survival; Cells, Cultured; Central Nervous System Stimulants; Dise | 2009 |
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Sti | 2009 |
Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agen | 2010 |
Modeling Parkinson's disease genetics: altered function of the dopamine system in Adh4 knockout mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Amphetamine; Analysis of Variance; Animals; A | 2011 |
An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Cell Line; Disease Models, Animal; Dopamine Agents; Enzyme-Linked Immunosorben | 2010 |
Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavioral Symptoms; Cell Count; Central Nervous System Stimulants; Disease Mo | 2011 |
GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Topics: Amphetamine; Animals; Animals, Genetically Modified; Cell Count; Corpus Striatum; Disease Models, An | 2011 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System S | 2011 |
Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Topics: alpha-Synuclein; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Behavioral Sympto | 2012 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinso | 2012 |
Is nicotine protective against Parkinson's disease? An experimental analysis.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease | 2012 |
Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease.
Topics: Aged; Amphetamine; Antiparkinson Agents; Drug Substitution; Female; Humans; Indans; Male; Methamphet | 2013 |
Adult human olfactory epithelial-derived progenitors: a potential autologous source for cell-based treatment for Parkinson's disease.
Topics: Adult; Amphetamine; Animals; Behavior, Animal; Cell Differentiation; Cell Movement; Cell Survival; C | 2012 |
The role of central amygdala dopamine in disengagement behavior.
Topics: Amphetamine; Amygdala; Animals; Behavior, Animal; Dopamine; Dopamine Antagonists; Dopamine Uptake In | 2013 |
The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Anim | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, | 2013 |
Behavioral/neurophysiological investigation of effects of combining a quinolinic acid entopeduncular lesion with a fetal mesencephalic tissue transplant in striatum of the 6-OHDA hemilesioned rat.
Topics: Amphetamine; Animals; Apomorphine; Brain Diseases; Brain Tissue Transplantation; Corpus Striatum; Do | 2003 |
Problems in the treatment of Parkinsonism by analeptics.
Topics: Amphetamine; Amphetamines; Apomorphine; Central Nervous System Stimulants; Humans; Parkinson Disease | 1956 |
[PRESENT STATUS OF THE TREATMENT OF PARKINSON'S DISEASE].
Topics: Alkaloids; Amphetamine; Histamine H1 Antagonists; Neurosurgery; Neurosurgical Procedures; Parkinson | 1964 |
Uptake of 6-[18F]fluoro-L-dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Behavior, Animal; Brain; Brain Mapping; Central | 2004 |
Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease.
Topics: Amphetamine; Animals; Cell Survival; Disease Models, Animal; Dopamine; Immunohistochemistry; Mice; M | 2004 |
Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Body Weight; Brain; Capsules; Cell Count; | 2004 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal | 2004 |
Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2005 |
Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Cell Count; Cell Tr | 2004 |
Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apoptosis; Behavior, Animal; Dep | 2005 |
Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Cell Line; Cell Transplantation; Disease | 2005 |
Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Cell Count; Cell Survival; Central Nervous System Stimulants | 2005 |
The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model.
Topics: Amphetamine; Animals; Cell Survival; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Respons | 2005 |
Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Be | 2005 |
Neurorescue effects of VEGF on a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Body Weight; Brain; | 2005 |
Transplants of neurosphere cell suspensions from aged mice are functional in the mouse model of Parkinson's.
Topics: Aging; Amphetamine; Animals; Apomorphine; Astrocytes; Behavior, Animal; Behavioral Symptoms; Corpus | 2005 |
Olfactory ensheathing glial co-grafts improve functional recovery in rats with 6-OHDA lesions.
Topics: Amphetamine; Animals; Apomorphine; Astrocytes; Behavior, Animal; Brain; Cell Culture Techniques; Cel | 2005 |
Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; beta-Galactosidase; Central Nervous System Stim | 2005 |
Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor age.
Topics: Adenoviridae; Amphetamine; Animals; Cell Count; Disease Models, Animal; Dopamine; Female; Fetal Tiss | 2005 |
Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy.
Topics: Amphetamine; Animals; Disease Models, Animal; Dopamine; Female; Fetal Tissue Transplantation; Male; | 2005 |
Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antigens; Behavior, Animal; Bromodeox | 2006 |
Amphetamine exposure is elevated in Parkinson's disease.
Topics: Adrenergic Agents; Aged; Amphetamine; Amphetamine-Related Disorders; Amyotrophic Lateral Sclerosis; | 2006 |
Amphetamine induced rotation in the assessment of lesions and grafts in the unilateral rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Central Nervous System Stimulants; Dopamine; Dos | 2007 |
High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users.
Topics: Amphetamine; Amphetamines; Antiparkinson Agents; Chromatography, High Pressure Liquid; Hair; Humans; | 2006 |
Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
Topics: alpha-Synuclein; Amphetamine; Animals; Apomorphine; Behavior, Animal; Benserazide; Brain; Disease Mo | 2006 |
Bridging nigrostriatal pathway with fibroblast growth factor-primed peripheral nerves and fetal ventral mesencephalon transplant recuperates from deficits in parkinsonian rats.
Topics: Amphetamine; Animals; Behavior, Animal; Cell Transplantation; Corpus Striatum; Fetus; Fibroblast Gro | 2006 |
Effect of ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in Parkinsonian rats. In vivo microdialysis study.
Topics: Amphetamine; Animals; Animals, Newborn; Disease Models, Animal; Dopamine; Ketanserin; Male; Microdia | 2006 |
Improved survival of young donor age dopamine grafts in a rat model of Parkinson's disease.
Topics: Age Factors; Amphetamine; Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Count; Cell | 2007 |
Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Disease Models, Animal; Dopamin | 2007 |
Adjunctive use of the non-ionic surfactant Poloxamer 188 improves fetal dopaminergic cell survival and reinnervation in a neural transplantation strategy for Parkinson's disease.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Cell Survival; Cell Transplantation; C | 2008 |
Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures.
Topics: Amphetamine; Animals; Antioxidants; Apomorphine; Behavior, Animal; Cell Line, Tumor; Corpus Striatum | 2008 |
Survival, differentiation, and migration of bioreactor-expanded human neural precursor cells in a model of Parkinson disease in rats.
Topics: Amphetamine; Animals; Behavior, Animal; Bioreactors; Cell Differentiation; Cell Movement; Cell Survi | 2008 |
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigrostriatal lesion in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Corpus Striatum; De | 1984 |
Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease.
Topics: Amphetamine; Humans; Hydrogen-Ion Concentration; Methamphetamine; Parkinson Disease; Phenethylamines | 1983 |
The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.
Topics: Amphetamine; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrogen-Ion Concentration; Lev | 1982 |
Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamine; Animals; Behavior, Animal; | 1994 |
Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Female; Male; Motor Activity; Oxidopam | 1993 |
BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Brain Tissue Transplantation; Brain-Derived Neu | 1996 |
Foetal nigral cell suspension grafts influence dopamine release in the non-grafted side in the 6-hydroxydopamine rat model of Parkinson's disease: in vivo voltammetric data.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Disease Models, Animal; Dopamine; Female; Oxidop | 1996 |
Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: an argument for neurotrophic supplementation.
Topics: Aging; Amphetamine; Animals; Behavior, Animal; Cell Division; Cell Size; Cell Survival; Dopamine; Ma | 1999 |
Functional integration of neural grafts in Parkinson's disease.
Topics: Amphetamine; Binding Sites; Brain Tissue Transplantation; Controlled Clinical Trials as Topic; Dopam | 1999 |
Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer.
Topics: Adrenergic Agents; Amphetamine; Animals; Brain-Derived Neurotrophic Factor; Central Nervous System S | 1999 |
Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
Topics: Adenoviridae; Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Brain; Dopamine; Dopamin | 1999 |
Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
Topics: Amphetamine; Animals; Corpus Striatum; Dopamine; Female; Glial Cell Line-Derived Neurotrophic Factor | 2001 |
Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model.
Topics: Adrenergic Agents; Amphetamine; Animals; Cell Culture Techniques; Cell Transplantation; Dopamine; Do | 2002 |
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; alpha-Synuclein; Amphetamine; Animals; Behavior | 2002 |
2-Phenylethylamine and amphetamine in human brain: effects of L-deprenyl in Parkinson's disease [proceedings].
Topics: Amphetamine; Brain; Humans; Parkinson Disease; Phenethylamines; Selegiline; Tissue Distribution | 1979 |
[Biochemical studies of schizophrenia].
Topics: Adenylyl Cyclase Inhibitors; Amphetamine; Brain; Dopamine; Haloperidol; Humans; Parkinson Disease; S | 1976 |
Levodopa-induced myoclonus.
Topics: 5-Hydroxytryptophan; Aged; Amantadine; Amphetamine; Animals; Benztropine; Dopamine Antagonists; Dose | 1975 |
Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Guinea Pigs; Humans | 1975 |
[The phenomenon of experimental motor retardation as one of the manifestations of the Parkinsonian syndrome].
Topics: Amphetamine; Animals; Catecholamines; Cats; Caudate Nucleus; Chlorpromazine; Dihydroergotoxine; Dise | 1975 |
Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior.
Topics: Amphetamine; Animals; Apomorphine; Axons; Denervation; Disease Models, Animal; Female; Motor Activit | 1991 |
Changes in blood-brain barrier permeability are associated with behavioral and neurochemical indices of recovery following intraventricular adrenal medulla grafts in an animal model of Parkinson's disease.
Topics: Adrenal Medulla; Amphetamine; Animals; Apomorphine; Behavior, Animal; Blood-Brain Barrier; Capillary | 1991 |
The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain Tissue Transplantation; Carbidopa; Corpus | 1990 |
Mechanisms of action of adrenal medulla grafts: the possible role of peripheral and central dopamine systems.
Topics: Adrenal Medulla; Adrenalectomy; Amphetamine; Animals; Apomorphine; Blood-Brain Barrier; Cerebral Ven | 1990 |
A functional assessment of embryonic dopaminergic grafts in the marmoset.
Topics: Amphetamine; Animals; Apomorphine; Brain Tissue Transplantation; Callitrichinae; Corpus Striatum; Di | 1990 |
Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release.
Topics: Amphetamine; Animals; Antibodies; Apomorphine; Behavior, Animal; Brain; Dialysis; Dopamine; Female; | 1988 |
Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain; Disease Models, Animal; Ergolines; Levod | 1987 |
Dopaminergic and cholinergic mechanisms in relation to postural tremor in the monkey and circling movements in the cat.
Topics: Acetylcholine; Amphetamine; Animals; Cats; Corpus Striatum; Disease Models, Animal; Dopamine; Fronta | 1974 |
The relationship between the inhibition of dopamine uptake and the enhancement of amphetamine stereotypy.
Topics: Amantadine; Amphetamine; Animals; Behavior, Animal; Chlorpheniramine; Dopamine; Dopamine Antagonists | 1971 |
The use of amphetamine induced stereotyped behaviour as a model for the experimental evaluation of antiparkinson agents.
Topics: Amphetamine; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Drug Synergism; | 1972 |
Corpus striatum in paralysis agitans and in perphenazine-injected rats.
Topics: Aged; Amphetamine; Amphetamines; Animals; Basal Ganglia; Caudate Nucleus; Chlorpromazine; Corpus Str | 1974 |
Amphetamines, valuable adjunct in treatment of Parkinsonism.
Topics: Aged; Amphetamine; Dextroamphetamine; Dihydroxyphenylalanine; Humans; Methylphenidate; Parkinson Dis | 1973 |
Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Drinking Behavior; Elect | 1974 |
A dopaminergic-cholinergic mechanism in production of psychotic symptoms.
Topics: Amphetamine; Animals; Brain; Brain Chemistry; Dopamine; Humans; Models, Biological; Parasympatholyti | 1973 |
Drug-induced movement disorders.
Topics: Amphetamine; Contraceptives, Oral; Dihydroxyphenylalanine; Dystonia Musculorum Deformans; Female; Hu | 1971 |
[Experimental and clinical data on the mechanism of action of amantadine and on its effectiveness in Parkinson's disease].
Topics: Acetylcholine; Aged; Amantadine; Amphetamine; Animals; Brain; Female; Guinea Pigs; Humans; Male; Mid | 1971 |
Different effects of drugs before and after stereotaxic operation.
Topics: Amphetamine; Dihydroxyphenylalanine; Globus Pallidus; Humans; Movement Disorders; Parkinson Disease; | 1966 |
[L-dopa and amphetamine treatment of acinetic Parkinsonism patients with and without stereotaxic surgery].
Topics: Amphetamine; Dihydroxyphenylalanine; Humans; Parkinson Disease; Stereotaxic Techniques | 1966 |
[The effect of phenamine on medicinal parkinsonism and retardation of movement upon stimulation of the caudate nucleus (a clinico-experimental study)].
Topics: Amphetamine; Caudate Nucleus; Female; Haloperidol; Humans; Male; Parkinson Disease; Parkinson Diseas | 1970 |
[A contribution to the biochemical treatment of the akinetic type of the Parkinson's syndrome].
Topics: Amphetamine; Dihydroxyphenylalanine; Drug Synergism; Humans; Injections, Intravenous; Monoamine Oxid | 1968 |